Paradigm Biopharmaceuticals Limited

Informe acción ASX:PAR

Capitalización de mercado: AU$77.1m

Paradigm Biopharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Paradigm Biopharmaceuticals's earnings have been declining at an average annual rate of -29.1%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 73.9% per year.

Información clave

-29.1%

Tasa de crecimiento de los beneficios

-19.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 9.6%
Tasa de crecimiento de los ingresos-73.9%
Rentabilidad financiera-246.4%
Margen neton/a
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17
Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20
Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07
Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22
Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24
We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29
When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Paradigm Biopharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

ASX:PAR Ingresos, gastos y beneficios (AUD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 240-59758
31 Mar 240-64665
31 Dec 230-69671
30 Sep 230-60762
30 Jun 230-52753
31 Mar 230-48948
31 Dec 220-441043
30 Sep 220-42941
30 Jun 220-39939
31 Mar 220-40939
31 Dec 210-411040
30 Sep 210-371037
30 Jun 210-341034
31 Mar 210-31730
31 Dec 20-1-28527
30 Sep 200-20420
30 Jun 200-12314
31 Mar 202-14412
31 Dec 194-1649
30 Sep 193-1648
30 Jun 193-1648
31 Mar 193-1137
31 Dec 183-737
30 Sep 183-727
30 Jun 183-627
31 Mar 182-626
31 Dec 172-525
30 Sep 172-525
30 Jun 172-424
31 Mar 172-424
31 Dec 161-424
30 Sep 161-423
30 Jun 161-313
31 Mar 161-322
31 Dec 150-211
30 Sep 150-211
30 Jun 150-210

Ingresos de calidad: PAR is currently unprofitable.

Margen de beneficios creciente: PAR is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: PAR is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.

Acelerando crecimiento: Unable to compare PAR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: PAR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).


Rentabilidad financiera

Alta ROE: PAR has a negative Return on Equity (-246.38%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado